Elite Pharmaceuticals Inc Stock Price, News & Analysis

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) will release its second quarter financial results for the fiscal year 2022 on November 15, 2021. A live conference call is scheduled for November 16 at 11:30 AM EST, where management will discuss financial and operating results, alongside a business update. Stakeholders are encouraged to submit questions before the call. Elite Pharmaceuticals focuses on developing niche generic products and operates a cGMP facility in Northvale, NJ. For more details, visit www.elitepharma.com.

Elite Pharmaceuticals (OTCQB:ELTP) reported a 6% decline in total revenues for Q1 FY 2022, reaching $7.1 million compared to $7.5 million in the same period last year. This decrease is attributed to the timing of sales of Amphetamine products. However, the company reported stronger margins leading to operating profits of $1.0 million, an increase of $0.2 million year-over-year, and net income of $2.4 million. A conference call is scheduled for August 17, 2021, to discuss the results further.

Elite Pharmaceuticals (OTCQB:ELTP) announced the release of its first quarter financial results for fiscal year 2022 on August 16, 2021. A live conference call to discuss these results and provide a business update is scheduled for August 17, 2021, at 11:30 AM EDT. Stakeholders are encouraged to submit questions ahead of the call. The company specializes in developing niche generic pharmaceutical products and operates a cGMP and DEA registered facility in Northvale, NJ.

Elite Pharmaceuticals reported a significant increase in fiscal year 2021 revenues, totaling $25.4 million, up 41% from the prior year. The revenue growth is primarily driven by sales of generic Adderall and Isradipine products. Operating profits rose to $2.1 million, a substantial improvement of $4.3 million year-over-year, with net income reported at $5.1 million. A conference call is scheduled for June 15, 2021, to discuss these results and future business developments.

Elite Pharmaceuticals (OTCBB:ELTP) will release its 2021 year-end financial results on June 14, 2021. A live conference call is scheduled for June 15 at 11:30 AM EDT to discuss the financials and provide a business update. Stockholders are encouraged to submit questions before the call. The financial statements will be available in the 10-K report. Elite develops and manufactures niche generic pharmaceuticals and operates a GMP facility in Northvale, NJ. This announcement sets the stage for potentially significant financial insights for the company.

Elite Pharmaceuticals announced a partnership with Prasco, LLC for the exclusive distribution of its generic Loxapine capsules. This agreement allows Prasco to manage sales and marketing in the US, while Elite will handle manufacturing. Loxapine, indicated for treating schizophrenia, is currently on the FDA drug shortage list, indicating a critical need for its availability. Prasco's infrastructure aims to ensure nationwide access, improving supply in the healthcare market.

Elite Pharmaceuticals has announced the appointment of Marc Bregman, CPA, as the new Chief Financial Officer, effective May 17, 2021. With over 27 years of experience, Bregman has held significant financial roles at various companies, enhancing his expertise in financial accounting and compliance. President and CEO Nasrat Hakim expressed confidence that Bregman's leadership will be pivotal for Elite's growth. Elite Pharmaceuticals specializes in developing niche generic products and operates a cGMP facility in Northvale, NJ.

Elite Pharmaceuticals Reports Q3 2021 Results

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) announced a 20% increase in consolidated revenues for the third quarter of fiscal year 2021, reaching $6.0 million. This marks the company's seventh consecutive quarter of revenue growth, with an average annual increase of 122%. Key revenue drivers included the launch of generic extended-release Adderall® and increased sales of generic immediate-release Adderall® and Dantrolene capsules. Operating income also improved to $1.0 million, up from $0.7 million in Q3 of the previous year.

Elite Pharmaceuticals (ELTP) will announce its third-quarter financial results on February 16, 2021. A conference call is scheduled for February 17, 2021, at 11:30 AM EST to discuss the results and provide a business update. The call will address questions submitted by stockholders. Elite Pharmaceuticals focuses on developing niche generic products and operates a cGMP and DEA registered facility in Northvale, NJ. Forward-looking statements in the release highlight potential risks and uncertainties.